Fennec Pharmaceuticals Inc. Q4 2025 Earnings Call Summary

Achieved record net product sales of $44.6 million in 2025, a 50% year-over-year increase driven by expanding active patient counts and new account acquisition. Strategic pivot toward the Adolescent and Young Adult (AYA) market, which management identifies as ten times larger than the core pediatric segment. Enhanced commercial execution through a 70% conversion rate in the Fennec HEARS program, up from 50% in Q1, by reducing administrative and reimbursement friction. Strengthened financial health b ...